Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia.
about
Factors influencing adherence to cancer treatment in older adults with cancer: a systematic reviewImportance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian settingSummary of the published Indian data on chronic myeloid leukemiaOral antineoplastic agents: how do we care about adherence?The role of observational studies in optimizing the clinical management of chronic myeloid leukemiaChronic Myeloid Leukemia in India.Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysisFactors influencing adherence to imatinib in Indian chronic myeloid leukemia patients: a cross-sectional study.Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy.Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.A Systematic Review of Adherence to Oral Antineoplastic TherapiesAdherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital.Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort.Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia.Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia.Adherence to oral antineoplastic agents by cancer patients: definition and literature review.A review of economic impact of targeted oral anticancer medications.Insights on practice variations in the management of lymphoma and leukemia.Improving adherence to oral cancer therapy in clinical practice.Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients.Adherence to imatinib among patients attending Saskatchewan Cancer Agency Pharmacies.Facilitators and Barriers to Self-Management for Adolescents and Young Adults Following a Hematopoietic Stem Cell Transplant.Culture, Styles of Institutional Interactions, and Inequalities in Healthcare Experiences.Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents.Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia.Magic pills: new oral drugs to treat chronic lymphocytic leukemia.BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Symptom Burden and Quality of Life Issues among Patients of Chronic Myeloid Leukemia on Long-term Imatinib TherapyEvaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.Why are patients with chronic myeloid leukaemia (non-)adherent?Understanding and Challenges in Taking Tyrosine Kinase Inhibitors among Malaysian Chronic Myeloid Leukemia Patients: A Qualitative StudyMedication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.Chronic myeloid leukaemia and human immunodeficiency virus (HIV) infection.A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors.Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study.
P2860
Q26850736-BAB58FC7-5DAA-460D-8ABE-B8AB689AF628Q27008389-3C6D6F72-C749-4A5D-92B8-52455037E8BDQ28075574-915EDCFA-EA2A-46B5-A63F-0E69E84B368EQ28082909-F6799B9F-5AE4-46DF-BB39-31E3A2C2D5DDQ28085149-2B78F89D-618D-4808-92E9-0151CD67F68AQ33859551-251A8322-2922-4A1C-9EA7-BAF274DB1B7CQ34445704-C039B7F0-1AB6-414F-836C-110F70C6BD08Q35130028-9628FCD2-7F9C-4976-B8D7-7225B8D4F81EQ36355098-91C2807A-69FE-4190-A7B2-28F126405EC0Q36364850-3630256A-AF5A-4A40-971A-A3874DBF9352Q36673490-ADE418FD-74C3-4039-9177-113C231BAA99Q37057014-A4A8B543-814B-48C4-ADB9-37D81054F618Q37365606-33A2A499-CDF1-4CC4-87B0-2A7F1A14EBCEQ37517333-B377BC36-9B90-41F1-B9DD-F86D7BDF799BQ37618888-E704D6EB-932A-4BF3-AE46-8A1795E4CC44Q37628623-9EF62177-8321-4CA0-84D7-4EE2E17A1793Q37999726-DEB14D3F-9E3B-4FB2-A4AE-2A96E5958FA0Q38109527-65502325-C21F-4082-B2B0-49F9A6DE3480Q38147533-F855586C-86B8-4CF4-BE9D-7AF9E4D49A1FQ38174702-AABFB871-D807-4F35-9CB7-DE7B6A178BABQ38177354-B674A56D-F4C4-4954-9DAF-06B15A1DCEA1Q38216035-9407508C-F2E7-40A7-9B87-5971A49B2E7BQ38356369-8C6454D1-328C-478C-A3C6-F60D516C3802Q38428850-12F79D8A-EA00-4D67-96B8-6BC65BD24D2CQ38635342-5AF71563-1DF9-4368-99B1-FEC4C79FDDB7Q38702545-A5227B93-E3F1-4DEB-B485-978EA8C2C2B2Q38725806-3074C45F-5893-4240-9966-9A3E1F484A98Q38880261-609347DD-3D4B-439C-8B31-AA4258C0C31DQ38943877-4947969A-994E-4985-940A-218B3B9C299DQ39350678-61A41AB1-082B-44A2-94D1-91AE91D0E8A4Q41601810-74AEB31D-6C6D-47BB-B7B6-0BB5A4FA74D5Q42395994-7F1575B5-5D7C-4274-A977-88C355FB9B84Q42511529-F5B39312-F6B0-4438-B3F9-2DE2DEC4DCE8Q42672759-9ABDC319-4AF1-46EE-922F-0E3CB53EC9CFQ44278420-C2F30B5B-F23F-4533-9347-47D6279EACB9Q45358123-9F81BE5C-CD0C-4C17-9D63-F6C55DC48C1FQ46130279-F93CCD54-19FA-4C4B-8D75-61D190653286Q47912298-3906B752-51B1-4D73-BEE7-E37204FF97D7Q49888044-90FC91B7-EB61-424E-8389-AAD1B0F4892FQ50996253-0F621643-EABA-4291-B9C1-3FDD9ACB5C28
P2860
Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Nonadherence to imatinib adver ...... hase chronic myeloid leukemia.
@en
Nonadherence to imatinib adver ...... hase chronic myeloid leukemia.
@nl
type
label
Nonadherence to imatinib adver ...... hase chronic myeloid leukemia.
@en
Nonadherence to imatinib adver ...... hase chronic myeloid leukemia.
@nl
prefLabel
Nonadherence to imatinib adver ...... hase chronic myeloid leukemia.
@en
Nonadherence to imatinib adver ...... hase chronic myeloid leukemia.
@nl
P2093
P2860
P356
P1476
Nonadherence to imatinib adver ...... phase chronic myeloid leukemia
@en
P2093
Biswajit Dubashi
Krishnarathinam Kannan
Manjunath Nandennavar
Rejiv Rajendranath
Sanju Cyriac
Tenali Gnana Sagar
P2860
P304
P356
10.1002/AJH.22019
P577
2011-04-27T00:00:00Z